Xuewei Bai1,2, Hongyu Zhang2, Yamei Zhou1,2, Katsuya Nagaoka2, Jialin Meng3,4, Chengcheng Ji2, Dan Liu2, Xianghui Dong5, Kevin Cao2, Joud Mulla2, Zhixiang Cheng2, William Mueller2, Amalia Bay2, Grace Hildebrand2, Shaolei Lu6, Joselynn Wallace7, Jack R Wands2, Bei Sun1, Chiung-Kuei Huang2. 1. Department of Pancreatic and Biliary Surgery, First Affiliated Hospital of Harbin Medical University, Harbin, China. 2. Liver Research Center, Division of Gastroenterology & Liver Research Center, Warren Alpert Medical School of Brown University and Rhode Island Hospital, Providence, RI. 3. Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. 4. Institute of Urology & Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei, China. 5. Department of Pathology, The First Affiliated Hospital of Harbin Medical University, Harbin, P.R. China. 6. Department of Pathology and Laboratory Medicine, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, RI. 7. Center for Computational Biology of Human Disease and Center for Computation and Visualization, Brown University, Providence, RI.
Abstract
BACKGROUND AND AIMS: Cholangiocarcinoma (CCA) is a highly lethal disease without effective therapeutic approaches. The whole-genome sequencing data indicate that about 20% of patients with CCA have isocitrate dehydrogenase 1 (IDH1) mutations, which have been suggested to target 2-oxoglutarate (OG)-dependent dioxygenases in promoting CCA carcinogenesis. However, the clinical study indicates that patients with CCA and mutant IDH1 have better prognosis than those with wild-type IDH1, further complicating the roles of 2-OG-dependent enzymes. APPROACH AND RESULTS: This study aimed to clarify if ten-eleven translocation 1 (TET1), which is one of the 2-OG-dependent enzymes functioning in regulating 5-hydroxymethylcytosine (5hmC) formation, is involved in CCA progression. By analyzing The Cancer Genome Atlas (TCGA) data set, TET1 mRNA was found to be substantially up-regulated in patients with CCA when compared with noncancerous bile ducts. Additionally, TET1 protein expression was significantly elevated in human CCA tumors. CCA cells were challenged with α-ketoglutarate (α-KG) and dimethyl-α-KG (DM-α-KG), which are cosubstrates for TET1 dioxygenase. The treatments with α-KG and DM-α-KG promoted 5hmC formation and malignancy of CCA cells. Molecular and pharmacological approaches were used to inhibit TET1 activity, and these treatments substantially suppressed 5hmC and CCA carcinogenesis. Mechanistically, it was found that knockdown of TET1 may suppress CCA progression by targeting cell growth and apoptosis through epigenetic regulation. Consistently, targeting TET1 significantly inhibited CCA malignant progression in a liver orthotopic xenograft model by targeting cell growth and apoptosis. CONCLUSIONS: Our data suggest that expression of TET1 is highly associated with CCA carcinogenesis. It will be important to evaluate TET1 expression in CCA tumors before application of the IDH1 mutation inhibitor because the inhibitor suppresses 2-hydroxyglutarate expression, which may result in activation of TET, potentially leading to CCA malignancy.
BACKGROUND AND AIMS: Cholangiocarcinoma (CCA) is a highly lethal disease without effective therapeutic approaches. The whole-genome sequencing data indicate that about 20% of patients with CCA have isocitrate dehydrogenase 1 (IDH1) mutations, which have been suggested to target 2-oxoglutarate (OG)-dependent dioxygenases in promoting CCA carcinogenesis. However, the clinical study indicates that patients with CCA and mutant IDH1 have better prognosis than those with wild-type IDH1, further complicating the roles of 2-OG-dependent enzymes. APPROACH AND RESULTS: This study aimed to clarify if ten-eleven translocation 1 (TET1), which is one of the 2-OG-dependent enzymes functioning in regulating 5-hydroxymethylcytosine (5hmC) formation, is involved in CCA progression. By analyzing The Cancer Genome Atlas (TCGA) data set, TET1 mRNA was found to be substantially up-regulated in patients with CCA when compared with noncancerous bile ducts. Additionally, TET1 protein expression was significantly elevated in human CCA tumors. CCA cells were challenged with α-ketoglutarate (α-KG) and dimethyl-α-KG (DM-α-KG), which are cosubstrates for TET1 dioxygenase. The treatments with α-KG and DM-α-KG promoted 5hmC formation and malignancy of CCA cells. Molecular and pharmacological approaches were used to inhibit TET1 activity, and these treatments substantially suppressed 5hmC and CCA carcinogenesis. Mechanistically, it was found that knockdown of TET1 may suppress CCA progression by targeting cell growth and apoptosis through epigenetic regulation. Consistently, targeting TET1 significantly inhibited CCA malignant progression in a liver orthotopic xenograft model by targeting cell growth and apoptosis. CONCLUSIONS: Our data suggest that expression of TET1 is highly associated with CCA carcinogenesis. It will be important to evaluate TET1 expression in CCA tumors before application of the IDH1 mutation inhibitor because the inhibitor suppresses 2-hydroxyglutarate expression, which may result in activation of TET, potentially leading to CCA malignancy.
Authors: Linda B C Bralten; Nanne K Kloosterhof; Rutger Balvers; Andrea Sacchetti; Lariesa Lapre; Martine Lamfers; Sieger Leenstra; Hugo de Jonge; Johan M Kros; Erwin E W Jansen; Eduard A Struys; Cornelis Jakobs; Gajja S Salomons; Sander H Diks; Maikel Peppelenbosch; Andreas Kremer; Casper C Hoogenraad; Peter A E Sillevis Smitt; Pim J French Journal: Ann Neurol Date: 2011-03 Impact factor: 10.422
Authors: Hao Wu; Ana C D'Alessio; Shinsuke Ito; Kai Xia; Zhibin Wang; Kairong Cui; Keji Zhao; Yi Eve Sun; Yi Zhang Journal: Nature Date: 2011-03-30 Impact factor: 49.962
Authors: Yanxin Lu; Jakub Kwintkiewicz; Yang Liu; Katherine Tech; Lauren N Frady; Yu-Ting Su; Wendy Bautista; Seog In Moon; Jeffrey MacDonald; Matthew G Ewend; Mark R Gilbert; Chunzhang Yang; Jing Wu Journal: Cancer Res Date: 2017-02-15 Impact factor: 12.701
Authors: Kuang-Hsiang Chuang; Christa L Whitney-Miller; Chin-Yi Chu; Zhongren Zhou; M Katherine Dokus; Shannon Schmit; Christopher T Barry Journal: Hepatology Date: 2015-05-06 Impact factor: 17.425
Authors: Satoshi Inoue; Wanda Y Li; Alan Tseng; Isabel Beerman; Andrew J Elia; Sean C Bendall; François Lemonnier; Ken J Kron; David W Cescon; Zhenyue Hao; Evan F Lind; Naoya Takayama; Aline C Planello; Shu Yi Shen; Alan H Shih; Dana M Larsen; Qinxi Li; Bryan E Snow; Andrew Wakeham; Jillian Haight; Chiara Gorrini; Christian Bassi; Kelsie L Thu; Kiichi Murakami; Alisha R Elford; Takeshi Ueda; Kimberly Straley; Katharine E Yen; Gerry Melino; Luisa Cimmino; Iannis Aifantis; Ross L Levine; Daniel D De Carvalho; Mathieu Lupien; Derrick J Rossi; Garry P Nolan; Rob A Cairns; Tak W Mak Journal: Cancer Cell Date: 2016-07-14 Impact factor: 31.743
Authors: Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner Journal: N Engl J Med Date: 2009-02-19 Impact factor: 176.079
Authors: Mehmet G Badur; Thangaselvam Muthusamy; Seth J Parker; Shenghong Ma; Samuel K McBrayer; Thekla Cordes; Jose H Magana; Kun-Liang Guan; Christian M Metallo Journal: Cell Rep Date: 2018-10-23 Impact factor: 9.423
Authors: Kohei Fujikura; Zainab I Alruwaii; Michael C Haffner; Maria A Trujillo; Nicholas J Roberts; Seung-Mo Hong; Anne Macgregor-Das; Michael G Goggins; Sujayita Roy; Alan K Meeker; Ding Ding; Michael Wright; Jin He; Ralph H Hruban; Laura D Wood Journal: J Pathol Date: 2021-05-21 Impact factor: 9.883